Online inquiry

IVTScrip™ mRNA-Human ANKRD46, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WK16128MR)

This product GTTS-WK16128MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the ANKRD46 protein. This product can be used in Oogenesis phase fetal germ cell-related researches.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Human
RefSeq NM_001270377.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification Chromatography
Target Gene
Gene ID 157567
UniProt ID Q86W74
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Human ANKRD46, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WK16128MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WK12274MR IVTScrip™ mRNA-Human ADTRP, (Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ADTRP
GTTS-WK15598MR IVTScrip™ mRNA-Human APBB1, (Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA APBB1
GTTS-WK10657MR IVTScrip™ mRNA-Human ACTA2, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ACTA2
GTTS-WK11689MR IVTScrip™ mRNA-Human AGAP3, (Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AGAP3
GTTS-WK27478MR IVTScrip™ mRNA-Human ARRDC1-AS1, (Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ARRDC1-AS1
GTTS-WK24444MR IVTScrip™ mRNA-Human ARL5A, (Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ARL5A
GTTS-WK4194MR IVTScrip™ mRNA-Human TM4SF1, (Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA TM4SF1
GTTS-WK15197MR IVTScrip™ mRNA-Human ANKRD10, (Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ANKRD10
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW